Deals ramp up in Asia's healthcare space with cancer focus

An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.

Related Keywords

China ,Lugano ,Ticino ,Switzerland ,Singapore ,Nanjing ,Jiangsu ,Hong Kong ,Sweden ,Shenzhen ,Guangdong ,Macau ,Japan ,Jilin ,United Kingdom ,Miami ,Florida ,United States ,Chinese ,Suno Biologics ,Garri Zmudze ,Sunho Biologics ,Pureos Bioventures ,Asia Pacific ,John Lee ,World Health Organisation ,Hong Kong Integrated Oncology Center ,Technology Innovation Zone ,Singapore Economic Development Board ,Hong Kong Stock Exchange ,Astrazeneca ,Haymarket Media ,Asia Summit On Global Health ,Frontier Group ,United Kingdom Swedish ,New Frontier Group ,Economic Development Board ,Nanjing City Based ,Greater Bay Area ,Special Adminstrative Regions ,Guangzhou United Familty Hospital ,New Frontier Shenzhen United Family ,New Frontier Greater Bay Area ,Asia Summit ,Global Health ,Hong Kong Shenzhenit Park ,Shenzhen Hong Kong Science ,Technology Innovation Co Operation ,